The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme

生物标志物是一种化学物质或信号，可以从人体测量，以帮助诊断疾病或预测未来的健康状况。生物标志物通常用于医疗保健指导患者管理，但在临床相关生物标志物的发现与在常规实践中实施以帮助患者之间存在主要的转化瓶颈。基因生物标记物尤其如此，它被定义为我们的遗传密码的变化，这种变化使我们易患疾病或预测治疗结果。其中许多都与“药物遗传学”有关，即基因密码的变化会影响我们对药物的反应。目前，基因测试的速度太慢，无法在日常实践中指导处方。传统的基因检测需要几周或几个月的时间才能得到结果，这对于大多数临床环境来说太慢了。然而，新技术有可能改变这种状况。生物技术公司面临的挑战是了解如何在给定的临床环境中最好地实施这些技术。该项目将通过与工业界、大学和医疗保健专业人员合作开发转化管道来解决这一问题，以支持时间紧迫的基因组测试技术的开发和实施（the dedicated program）。这建立在大曼彻斯特在该领域的世界领先声誉的基础上，使行业能够专注于技术开发的核心业务，而学术和临床合作伙伴则致力于确保所述技术具有成本效益，能够很好地投放市场，并且在设计时考虑到患者。将通过三个范例项目展示其价值。*开发一种用于指导中风患者治疗的快速基因床边检测（Genedrive plc & EMQN）。*使用新兴生物材料开发超快速基因检测，能够检测基因变化以指导抗生素治疗（Chromition Ltd和Epinal）。*创建一个全面的药物遗传学检测小组，并提供信息解决方案，以确保临床医生在需要时可以获得结果（APIS Assay Technologies Ltd & EMQN）。这些不同的项目将显示出“投入”方案的灵活性，其产出不仅将改善人口的健康，而且将创造宝贵的工业资产，从而在大曼彻斯特地区进一步投资。在该奖项的生命周期之后，该项目将继续与其他工业合作伙伴合作，以期在未来十年推动创新和技术转化。

A biomarker is a chemical or signal which can be measured from the human body to help to diagnose disease or predict future health states. Biomarkers are commonly used in healthcare to guide patient management, but there is a major translational bottleneck between the discovery of a clinically relevant biomarker and its implementation in routine practice to help patients. This is particularly true of genetic biomarkers, defined as changes in our genetic code which predispose to disease or predict treatment outcomes.Many of these are related to _pharmacogenetics_, the concept that changes in our genetic code influence our response to medicines. At present, genetic tests are too slow to guide prescribing in day-to-day practice. Traditional genetic tests take many weeks or months to come back, which is far too slow to be used in most clinical settings. However, new technologies have the potential to change this. The challenge for biotechnology companies is understanding how best to implement these technologies in a given clinical setting.This project will address this by developing a translational pipeline with collaboration between industry, Universities, and healthcare professionals to support the development and implementation of time critical genomic testing technologies (The DEVOTE Programme). This builds on Greater Manchester's world leading reputation in this space, empowering industry to focus on their core business of technology development, whilst academic and clinical partners work to ensure said technologies are cost effective, well placed in the market, and designed with patients in mind. DEVOTE will demonstrate its value through three exemplar projects.* Development of a rapid genetic bedside test to guide treatment for patients after stroke (Genedrive plc & EMQN).* Using new and emerging biomaterials to develop an ultra-rapid genetic test, capable of detecting genetic changes to guide antibiotic therapy (Chromition Ltd and Epinal).* Creation of a comprehensive pharmacogenetic testing panel with an informatic solution to ensure results are available to clinicians at the point of need (APIS Assay Technologies Ltd & EMQN).These varied projects will show the flexibility of the DEVOTE programme and the outputs will not only improve the health of the population, but will create valuable industrial assets, resulting in further investment across Greater Manchester. The DEVOTE programme will continue to engage with other industrial partners beyond the lifecycle of this award, with a view to drive innovation and the translation of technologies over the next decade.